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Abstract
Background:  The sweet taste inhibitor lactisole acts on the human sweet taste receptor
heteromer TAS1R2-TAS1R3 but not on its rodent counterpart. Recently, it was shown that the
lactisole sensitivity of the human sweet taste receptor involves the part of TAS1R3 encompassing
the seven transmembrane regions but not the huge N-terminal domain. Using mutational analysis
we investigated which amino acid residues distinguish lactisole insensitive rat from sensitive human
T1R3 receptors.
Results: The functional analysis of specific receptor mutants in HEK293T cells revealed that the
exchange of valine 738 in the fifth transmembrane domain of rTas1r3 by an alanine is sufficient to
confer lactisole sensitivity to the rat sweet taste receptor. The sensitivity of this receptor mutant
is ~2 fold lower than the sensitivity of the human sweet taste receptor. Additional substitution of
lysine 735 by phenylalanine in rTas1r3 results in a rat sweet taste receptor that is as sensitive to
lactisole as its human counterpart. The exchange of valine 738 to alanine was accompanied by a
~50% reduction in receptor efficacy. This effect was seen with all six different sweet compounds
examined.
Conclusion: The lactisole insensitivity of rat sweet taste receptor is caused by only two amino
acids in transmembrane region five, which is critical for the interaction of lactisole with the sweet
taste receptor. The observation that the mutant receptor simultaneously displays a generally
reduced sensitivity towards all agonists suggests that the lactisole insensitivity of the rodent
receptor might be more likely caused by the inaccessibility of the lactisole binding site rather then
by its direct disruption.
Background
Sweet and umami taste involve TAS1R receptors, which
belong to the subclass 3 of the GPCR super family and are
distantly related to the V2R pheromone-, metabotropic
glutamate- and calcium sensing receptors [1-3]. They have
a large N-terminal extracellular domain that is linked by a
cysteine-rich domain to the seven transmembrane
domains [2]. Heterologous expression and functional
analysis showed that cells co-transfected with Tas1R2-
TAS1R3 responded to a variety of natural and artificial
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sweeteners, while the combination TAS1R1-TAS1R3
responded to L-amino acids [3-5]. In line with observed
differences in the perception of these compounds
between humans and rodents [6-8], the artificial sweeten-
ers aspartame and cyclamate, and the sweet proteins
brazzein, monellin, and thaumatin only activate the
human but not the rodent TAS1R2-TAS1R3 heteromer
[2,3]. Further studies of mouse-human interspecies chi-
meras and point-mutated receptors revealed that cycla-
mate interacts with the part of hTAS1R3 encompassing
the seven transmembrane regions, whereas aspartame
interacts with the N-terminal domain of hTAS1R2 [9].
Moreover, the cysteine-rich motif in the N-terminal
domain of hTAS1R3 is required for the activation of the
sweet receptor by brazzein [2]. These results and modeling
studies on the basis of the solved X-ray structure of the
mGLUR1 ligand binding domain strongly suggest that
multiple sites in both receptor subunits are involved in
the activation of the sweet receptor by its ligands [9-12].
Interestingly, differences in taste perception are not lim-
ited to sweet compounds but also have been observed for
2-(4-methoxphenoxy) propanoic acid sodium salt (lacti-
sole), which suppresses the sweet taste of various com-
pounds in humans but not in rats [3,13-17]. Functional
studies of the human and rat sweet taste receptor recently
showed that lactisole inhibits the human TAS1R2-TAS1R3
heteromer but not that of rats [3]. Moreover it could be
shown that that the lactisole sensitivity of the human
sweet taste receptor involves the TAS1R3 subunit [9].
Thus, the inhibition of the sweet response by lactisole in
humans is due to structural differences between the rat
and human sweet taste receptor. Using mutational analy-
sis we investigated the molecular basis for these
differences.
Results and discussion
Application of the artificial sweetener saccharin to
HEK293T-Gα16gust44 cells transfected with the cDNAs for
the rat sweet receptor rTas1r3-rTas1r2 or its human coun-
terpart hTAS1R3-hTAS1R2 elevated intracellular calcium
levels (Fig. 1a). The responses were dose-dependent with
half maximal effective concentrations (EC50) of 0.17 ±
0.04 mM for the human heteromer and of 1.28 ± 0.16
mM for the rat receptor heteromer. Thus, the rodent recep-
tor is ~7 fold less sensitive to saccharin than the human
receptor. This shows subtle functional differences
between the human and the rat sweet receptor. In addi-
tion to saccharin also other sweet tasting compounds of
various chemical classes such as the disacchride sucrose,
the dipeptide derivate aspartame, the sulfamate cycla-
mate, the dihydrochalcone neohesperidine dihydrochal-
cone, and the terpenoid glycoside stevioside the activated
the human receptor (Fig. 1b). Like its human counterpart,
the rat sweet taste receptor could be robustly activated by
saccharin, sucrose, and stevioside (Fig. 1c). But in contrast
to the human receptor, aspartame, cyclamate, and neo-
hesperidine dihydrochalcone did not activate the rat
receptor (Fig. 1c) which reflects species specific variations
in sweet taste perception [7,8].
Lactisole inhibited the responses of cells transfected with
the cDNAs for the human receptor to all tested sweeteners
(Fig. 1a, 1b) while it did not inhibit the responses of cells
transfected with the rat sweet receptor (Fig. 1a, 1c). This is
well in line with previous studies of the receptor function
[3,9]. Based on the inhibitory effect of lactisole on the
human but not on the rat receptor heteromer, we next
asked which amino acids cause the functional difference
of the receptors. We therefore analyzed cells co-trans-
fected with cDNAs of the interspecies sweet taste receptor
combinations, i.e. hTAS1R3-rTas1r2 or rTas1r3-hTAS1R2.
The combination hTAS1R2-rTas1r3 responded to aspar-
tame, saccharin, sucrose, and stevioside but not to cycla-
mate and neohesperidine dihydrochalcone (Fig. 1d). The
responses induced by all four agonists were lactisole
insensitive (Fig. 1d). The combination rTas1r2-hTAS1R3
clearly responded to the sweeteners cyclamate and neo-
hesperidine dihydrochalcone, although with markedly
reduced amplitudes. Aspartame, saccharin, sucrose, and
stevioside failed to activate this receptor combination
(Fig. 1e). This indicates that the hTAS1R3 subunit is
involved in the response of the human sweet taste recep-
tor to cyclamate and neohesperidine dihydrochalcone.
Notably, the responses were lactisole sensitive (Fig. 1e). In
line with previous observations [9] we therefore conclude
that the lactisole sensitivity is solely mediated by the
hTAS1R3 subunit.
Next we wanted to know which part of hTAS1R3 mediates
the sensitivity to lactisole. To address this point we con-
structed two chimeric receptors. In the receptor chimera
tas1r3-rN-hTM we fused the N-terminal domain of
rTas1r3 to the C-terminal part containing the transmem-
brane regions of hTAS1R3. In the complementary chimera
tas1r3-hN-rTM the human N-terminal domain was fused
to the segment of the rat subunit encompassing the trans-
membrane regions. Cells co-transfected with plasmids
encoding hTAS1R2 and tas1r3-hN-rTM responded to
aspartame, saccharin, sucrose, and stevioside but not to
cyclamate and neohesperidine dihydrochalcone (Fig. 2a).
The responses to all four agonists were lactisole insensi-
tive (Fig. 2a). Cells co-transfected with plasmids encoding
hTAS1R2 and tas1r3-rN-hTM responded to all sweeteners
tested (Fig. 2b). The responses to all six agonists were lac-
tisole sensitive (Fig. 2b). Based on these findings we con-
clude that the activation the human sweet receptor by
cyclamate and neohesperidine dihydrochalcone involves
the hTAS1R3 transmembrane regions. Moreover, the sen-
sitivity towards lactisole is determined by the hTAS1R3
transmembrane regions.BMC Neuroscience 2005, 6:22 http://www.biomedcentral.com/1471-2202/6/22
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Calcium responses in cells co-transfected with different rat  and human TAS1R subunits to stimulation with various sweet- eners in the presence and absence of lactisole Figure 1
Calcium responses in cells co-transfected with different rat 
and human TAS1R subunits to stimulation with various sweet-
eners in the presence and absence of lactisole. (a) Intracellu-
lar calcium traces recorded in the FLIPR. Upper panel: 
Responses of cells cotransfected with cDNAs hTAS1R2 and 
hTAS1R3. Lower panel: Response of cells co-transfected with 
cDNAs rTas1r2 and rTas1r3. The cells were challenged with 
3 mM saccharin containing 0.0, 0.01, 0.1, or 1.0 mM lactisole. 
Arrows denote the time of application. Signals were averaged 
over three independent wells of a FLIPR plate. Vertical scale, 
1000 counts; horizontal scale, 1 min. (b) Cells co-transfected 
with hTAS1R2-hTAS1R3, (c) rTas1r2-rTas1r3, (d) hTAS1R2-
rTas1r3, or (e) rTas1r2-hTAS1R3. c, response of mock-trans-
fected control cells; lac, 1.0 mM lactisole; asp, 15 mM aspar-
tame; cyc, 30 mM cyclamate; neo, 0.1 mM neohesperidine 
dihydrochalcone; sac, 10 mM saccharin; suc, 100 mM 
sucrose; stev, 1 mM stevioside; -, response without lactisole; 
+, response in the presence of 1.0 mM lactisole. All sweeten-
ers were used at concentrations which were close to the 
maximal obtainable signal.
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Effect of lactisole on Tas1r3 variants Figure 2
Effect of lactisole on Tas1r3 variants. (a) Calcium responses 
of cells co-transfected with hTAS1R2 and a Tas1r3 chimera 
comprising the human N-terminus and the rat transmem-
brane region or hTAS1R2 and a Tas1r3 chimera comprising 
the rat N-terminus and the human transmembrane region (b) 
to stimulation with various sweeteners in the presence and 
absence of lactisole. c, response of mock-transfected control 
cells; lac, 1.0 mM lactisole; asp, 15 mM aspartame; cyc, 30 
mM cyclamate; neo, 0.1 mM neohesperidine dihydrochal-
cone; sac, 10 mM saccharin; suc, 100 mM sucrose; stev, 1 
mM stevioside; -, response without lactisole; +, response in 
the presence of 1.0 mM lactisole. All sweeteners were used 
at concentrations which were close to the maximal obtaina-
ble signal. (c) Alignment of amino acid sequences of the 
human, rat, and mouse Tas1r3 transmembrane regions. 
Color code: white, identical; grey, conservative; dark-grey, 
similar; black, non-similar. TM, predicted transmembrane 
domain, indicated by a black bar. Dots indicate the location 
of the primer used to generate the chimeric rat-human 
Tas1r3 receptors. Asterisks denote amino acid positions that 
are identical in rat and mouse but variable between humans 
and rodents and are located in the extracellular loops or the 
upper part of the transmembran regions. Boxes indicate the 
several rTas1r3 mutants m1 – m7, including the amino acid 
substitutions. m6/1 – m6/3 signified the reconverted amino 
acid of mutant m6.
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Sequence comparisons (Fig. 2c) between hTAS1R3 and its
rat and mouse orthologs revealed 75 amino acid
differences in the transmembrane regions. As mice and
rats are lactisole insensitive while humans are lactisole
sensitive, we reasoned that the amino acids responsible
for this species difference are conserved in the rodent
receptors but variable between rodents and humans. We
therefore excluded 27 of the 75 amino acids because they
vary between rat and mouse. Due to the polar nature of
lactisole we assumed that it is membrane impermeable
and should therefore interact with amino acids that are
accessible from the extracellular site. Based on this
assumption we identified 17 amino acids (Fig. 2c, aster-
isks) as the most promising candidates. We assumed that
the conversion of one or several of these amino acids from
the rodent to the human form should confer the lactisole
sensitivity to the rat receptor. To test this hypothesis we
created seven rTas1r3 variants (m1 – m7) that contained
1–4 amino acids of hTAS1R3 (Fig. 2c, boxes). The func-
tional analysis of these receptor variants revealed that
receptor mutant m6 confered lactisole sensitivity to the
heteromer, while all other rTas1r3 mutants did not (Fig.
3a). Thus, the 3 amino acids exchanges L735F, V738A,
and I740A of mutant m6 are sufficient to confer lactisole
sensitivity to rTas1r3. To test whether all exchanges in m6
are equally important, we created three variants, m6/1,
m6/2 and m6/3 (Fig. 2c, boxes). In each of these, we
reconverted one of the three human amino acids present
in the mutant m6 back into that of the rat receptor. In case
the amino acid is important for the inhibition of the sweet
receptor, the variant should loose its lactisole sensitivity.
Only mutant m6/2, L735F and I740A, was lactisole insen-
sitive, while the two other variants m6/1, V738A and
I740A, and m6/3, L735F and V738A remained lactisole
sensitive (Fig. 3b). Thus, we concluded that the alanine to
valine exchange in position 738 in transmembrane seg-
ment 5 is crucial for the lactisole sensitivity. To confirm
this, we created a rTas1r3 variant where we only substi-
tuted the valine at amino acid position 738 by an alanine.
Functional analysis of this receptor variant, rTas1r3-
V738A, co-transfected with rTas1r2 revealed that it was
activated by saccharin, sucrose, and stevioside, but not by
aspartame, cyclamate and neohesperidine dihydrochal-
cone (Fig. 3c). Thus, rTas1r3-V738A shows the same ago-
nist profile as the wild type rat receptor (Fig. 3c, 1b).
However, in marked contrast to the rat wild type receptor,
the response of rTas1r3-V738A was always lactisole sensi-
tive (Fig. 3c).
To test if rTas1r3-V738A displays the same degree of lacti-
sole sensitivity as the human receptor, we determined the
half maximal inhibitory concentration (IC50) of lactisole
on rTas1r3-V738A and compared it with the IC50 values of
the human receptor and the mutants m6, m6/1, m6/2,
and m6/3. Although all variants except the lactisole insen-
sitive mutant m6/2 were inhibited by lactisole, we
observed subtle differences (Fig. 3d). The IC50 values were
0.05 ± 0.01 for the human receptor, 0.06 ± 0.01 for m6,
0.11 ± 0.01 m6/1, 0.05 ± 0.02 for m6/3 and 0.16 ± 0.03
for rTas1r3-V738A (Fig. 3d). Thus, the human receptor
and the mutants m6 and m6/3 behave identical while the
mutants m6/1 and rTas1r3-V738A are ~2 fold less lacti-
sole sensitive. This result shows that the replacement of
Effect of lactisole on Tas1r3 variants Figure 3
Effect of lactisole on Tas1r3 variants. (a, b) Responses of cells 
co-transfected with rTas1r2 and rTas1r3 mutants to stimula-
tion with 1 mM stevioside. (c) Calcium responses of cells co-
transfected with rTas1r2 and the rTas1r3-V738A receptor 
variant to stimulation with various sweeteners in the pres-
ence and absence of lactisole. c, response of mock-trans-
fected control cells; lac, 1.0 mM lactisole; asp, 15 mM 
aspartame; cyc, 30 mM cyclamate; neo, 0.1 mM neohesperid-
ine dihydrochalcone; sac, 10 mM saccharin; suc, 100 mM 
sucrose; stev, 1 mM stevioside; -, response without lactisole; 
+, response in the presence of 1.0 mM lactisole. All sweeten-
ers were used at concentrations which were close to the 
maximal obtainable signal. (d) Concentration-dependent inhi-
bition of calcium responses by lactisole in cells transfected 
with hTAS1R2-hTAS1R3 (open circles, solid line), rTas1r2-
rTas1r3 V738A (squares, dash-dot-dotted line), rTas1r2-
rTas1r3 m6 (open triangles up, long dashed line), rTas1r2-
rTas1r3 m6/1 (filled circles, short dashed line), rTas1r2-
rTas1r3 m6/2 (triangles down, medium dashed line) or 
rTas1r2-rTas1r3 m6/3 (open diamond, dotted line) that were 
challenged with 3 mM stevioside.
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lysine 735 by phenylalanine is required for full lactisole
sensitivity of the mutant rat receptor.
Notably, the gain of lactisole sensitivity in the
rodentTas1r3 variants m6, m6/3, m6/1, is accompanied
by a ~50% reduction of the signal amplitude compared to
the wild type rTas1r3 (Fig. 3a,3b). In marked contrast, the
loss of lactisole sensitivity by the rTas1r3 mutant m6/2 led
to an increase in the signal amplitude (Fig. 3b). The
diminished signal amplitudes are not caused by individ-
ual differences in the expression rates of the receptor vari-
ants (Fig. 4). Moreover the V738A receptor variant, that
contains just a single amino acid exchange also showed a
~50 % reduced amplitude compared to the native rat
sweet taste receptor (Fig. 3b, 3c). This reduction is inde-
pendent of the sweet taste agonist (Fig. 3c). The activation
of the TAS1R2-TAS1R3 receptor by different sweeteners
involves several receptor sites [9-12]. As the V738A amino
acid exchange leads to an agonist independent amplitude
reduction, this observation in combination with its
localization in the fifth transmembrane region argues for
a global or regional alteration of the receptor structure
instead of a specific change at the agonist binding sites.
Conclusion
The lactisole insensitivity of rat sweet taste receptor is
caused by valine 738 in transmembrane region five. The
additional replacement of a lysine residue by a phenyla-
lanine at amino acid position 735 again in transmem-
brane region five is sufficient to increases the lactisole
sensitivity of the mutant rat receptors to the level of the
human counterpart. Thus, transmembrane region five is
critical for the interaction of lactisole with the sweet recep-
tor. The observation that the mutant receptors displays a
generally reduced sensitivity towards all agonists suggests
that the lactisole insensitivity of the rodent receptor might
be more likely caused by an inaccessibility of the lactisole
binding site rather then by its direct disruption. Instead
the lactisole insensitivity of the rodent receptor more is
likely a side effect that is caused by a steric alteration in the
fifth transmembrane region of the rat TAS1R3 subunit
induced by the valine at amino acid 738. Recently func-
tional studies of the mouse and human sweet taste recep-
tor in combination with mutational analysis led to a
model of the lactisole binding site in human TAS1R3 [18].
This model predicts that the alanine 733 in human
TAS1R3 which corresponds to valine 738 of rat TAS1R3 is
not directly involved in lactisole binding although it lies
in close proximity to the lactisole binding pocket. The
proximity of this amino acid to the predicted lactisole
binding pocket further supports our conclusion that
valine 738 in rat sweet taste receptor prevents the access of
lactisole to its binding site.
Methods
Cloning of the TAS1R cDNAs
hTAS1R2 was constructed via amplification of all exons
from genomic DNA by recombinant polymerase chain
reactions (PCR) [19]. hTAS1R3  was cloned from testis
cDNA. rTas1r2 was cloned from rat vallate papillae cDNA.
PCR products were cloned into a pcDNA5/FRT expression
vector (Invitrogen), fused with a C-terminal FLAG-epitope
for immuncytochemical detection, sequenced, and
checked for comparable protein expression by immuncy-
tochemistry of transfected HEK293T cells.
Construction of chimeric receptor cDNAs
The receptor chimeras of Tas1r3 were constructed using
recombinant PCR. In the first reactions the N-terminal
and the C-terminal part containing the seven
transmembrane domains of hTAS1R3 and rTas1r3 were
amplified from plasmid DNA using Ultra Pfu Polymerase
(Stratagene). For the hTAS1R3 and rTas1r3 N-termini the
forward vector-anchored primer (CMV: CGCAAAT-
GGGCGGTAGGCGTG) and a reverse gene specific primer
(CACAGCCGGCTCGCCC) were used. The hTAS1R3 and
rTas1r3 C-terminal part were amplified with forward gene
specific primer (GGGCGAGCCGGCTGTG) and a reverse
vector-anchored primer (TAGAAGGCACAGTCGAGG).
PCR conditions were: 5 min, 94°C, 24 cycles 1 min 94°C,
0.5 min 64°C, 2 min 72°C; 5 min 72°C. The amplicons
were purified using the Highpure PCR Product
Expression of receptor variants Figure 4
Expression of receptor variants. The table shows the overall 
expression in % of all receptor constructs detected by 
immuncytochemistry (a), transmission and fluorescence pic-
tures of HEK293T/ Gα16gust44 cells transfected with rTas1r3 
(b), rTas1r3-V738A (c) or rTas1r3 m6/3 (d) DNA. Scale, 50 
µm.BMC Neuroscience 2005, 6:22 http://www.biomedcentral.com/1471-2202/6/22
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Purification Kit (Roche) and used as template for the sec-
ond PCR. To create the chimeric receptor tas1r3-hN-rTM,
equimolar amounts (~50 ng) of the hTAS1R3 N-terminus
and  rTas1r3  transmembrane domains were combined
without additional oligonucleotides. PCR conditions
were: 5 min 94°C; 15 cycles of 2 min 64°C, 2 min 72°C
and 0.5 min 94°C; followed by 5 min 64°C and 10 min
72°C. The identical protocol and combining the rTas1r3
N-terminus with the human transmembrane regions
resulted in receptor chimera tas1r3-rN-hTM. These chime-
ras were cloned into pcDNA5/FRT.
Construction of Tas1r3 mutants
Receptor mutants were generated by site directed muta-
genesis according to the QuikChange protocol (Strata-
gene). The forward and reverse complement primers
contained the desired mutations and annealed to the
same sequence on opposite strands of the plasmids. The
following rTas1r3 receptor variants were generated: m1:
S576L; m2: R632Q, S635P, S637Q; m3: M644L A645S;
m4: A702T; m5: Q717H, V718M, V723A, E725V; m6:
L735F, V738A, I740A. m6/1: V738A, I740A, m6/2: L735F,
I740A, m6/3: L735F, V738A. m7: A793V, Y794L, Q795R.
Subsequently a rTas1r3-V738A variant was generated. All
constructs were checked by sequencing.
Functional expression
The cDNAs were transiently transfected into HEK293T
cells stably expressing the chimeric G-protein subunit
Gα16gust44  [20] using Lipofectamine 2000 (Invitrogen)
according to the manufacturer's protocol. 3–4 hours after
transfection, DMEM was replaced by low-glucose DMEM
supplemented with GlutaMAX and 10% dialyzed FBS
(Invitrogen). 22–44 hours later, cells were loaded for 1
hour with the calcium sensitive dye Fluo4-AM (2 µg/ml in
DMEM, Molecular Probes). Cells were washed 3x in solu-
tion C1 (130 mM NaCl, 5 mM KCl, 10 mM Hepes, 2 mM
CaCl2, and 5 mM Glucose, pH 7,4). Calcium mobilization
was monitored by an automated fluorometric imaging
plate reader (FLIPR, Molecular Devices). Ligands (Sigma-
Aldrich, Merck) were dissolved in C1 solution. All data
were collected from at least two independent experiments
carried out in triplicate. The obtained calcium signals were
corrected for the response of mock transfected cells and
normalized to the fluorescence of cells prior to the stimu-
lus using ∆F/F=(F-F0)/F0. Concentration-response curves
and EC50 and IC50 values were calculated in SigmaPlot by
nonlinear regression using the function f = ((a-d)/(1+(x/
EC50)nH)+d) and f = (a-b)/ [1+(x/IC50)nH]+b respectively.
Immuncytochemistry
HEK-293T/Gα16gust44  cells were seeded on coverslips
coated with 10 µg/ml poly-D-lysine and transfected with
the respective cDNAs. 48 h after transfection cells were
washed with PBS and fixed and permeabilized for 5 min
in acetone:methanol (1:1). Non-specific binding was
reduced by incubating the cells in 5% goat serum for 1 h.
To detect the receptors, antiserum against the FLAG-
epitope (anti-FLAG M2 (Sigma), 1:2000 in 3% goat
serum) was added to the cells for 1 h at room temperature
(RT). After washing the cells three times with PBS we
added Alexa488-conjugated goat antiserum against
mouse IgG ((Molecular Probes), 1:1000 in 3% goat
serum) for 1 h at RT. The cells were embedded in Fluores-
cent Mounting Medium (Dako) and analyzed using a flu-
orescence microscope (Zeiss Axioplan, Jena) and a camera
(RT Slide, Visitron Systems, Munich).
List of abbreviations
GPCR G-protein coupled receptor
HEK293T/ Gα16gust44 Human embryonic kidney cells sta-
bly expressing the
large T antigen and the G protein chimera Gα16gust44
EC50 half maximal effective concentration
IC50 half maximal inhibitory concentration
FLIPR fluorometric imaging plate reader
Authors' contributions
MW cloned most of the TAS1R subunits, constructed the
chimeric TAS1R3 receptors and carried out all functional
studies. BB created the receptor variants m1–m7, partici-
pated in the study design and drafted the manuscript.
W.M conceived the study, participated in its design and
coordination and helped to draft the manuscript. All
authors read and approved the final manuscript.
Acknowledgements
We thank Jay Slack (Cincinnati) for the HEK293T Gα16gust44 cell line, Hartwig 
Schmale and Nicole Burhenne (Hamburg) for the rTas1r3 cDNA, and Konrad 
Hoppe for providing stevioside, cyclamate, and aspartame. This project was sup-
ported through DFG-grants ME 1024 / 1–2 and ME 1024 / 2-1.
References
1. Hoon MA, Adler E, Lindemeier J, Battey JF, Ryba NJ, Zuker CS: Puta-
tive mammalian taste receptors: a class of taste-specific
GPCRs with distinct topographic selectivity.  Cell 1999,
96:541-551.
2. Jiang P, Ji Q, Liu Z, Snyder LA, Benard LM, Margolskee RF, Max M:
The cysteine-Rich region of T1R3 determines responses to
intensely sweet protein. J Biol Chem 2004, 279:45068-45075.
3. Li X, Staszewski L, Xu H, Durick K, Zoller M, Adler E: Human
receptors for sweet and umami taste. Proc Natl Acad Sci U S A
2002, 99:4692-4696.
4. Nelson G, Hoon MA, Chandrashekar J, Zhang Y, Ryba NJ, Zuker CS:
Mammalian sweet taste receptors. Cell 2001, 106:381-390.
5. Nelson G, Chandrashekar J, Hoon MA, Feng L, Zhao G, Ryba NJ,
Zuker CS: An amino-acid taste receptor.  Nature 2002,
416:199-202.
6. Brouwer JN, Hellekant G, Kasahara Y, van der Wel H, Zotterman Y:
Electrophysiological study of the gustatory effects of thePublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Neuroscience 2005, 6:22 http://www.biomedcentral.com/1471-2202/6/22
Page 7 of 7
(page number not for citation purposes)
sweet proteins monellin and thaumatin in monkey, guinea
pig and rat. Acta Physiol Scand 1973, 89:550-557.
7. Sclafani A, Abrams M: Rats show only a weak preference for the
artificial sweetener aspartame. Physiol Behav 1986, 37:253-256.
8. Naim M, Rogatka H, Yamamoto T, Zehavi U: Taste responses to
neohesperidin dihydrochalcone in rats and baboon monkeys.
Physiol Behav 1982, 28:979-986.
9. Xu H, Staszewski L, Tang H, Adler E, Zoller M, Li X: Different func-
tional roles of T1R subunits in the heteromeric taste
receptors. Proc Natl Acad Sci U S A 2004, 101:14258-14263.
10. Tancredi T, Pastore A, Salvadori S, Esposito V, Temussi PA: Interac-
tion of sweet proteins with their receptor. A conformational
study of peptides corresponding to loops of brazzein, monel-
lin and thaumatin. Eur J Biochem 2004, 271:2231-2240.
11. Spadaccini R, Trabucco F, Saviano G, Picone D, Crescenzi O, Tancredi
T, Temussi PA: The mechanism of interaction of sweet pro-
teins with the T1R2-T1R3 receptor: evidence from the solu-
tion structure of G16A-MNEI. J Mol Biol 2003, 328:683-692.
12. Temussi PA: Why are sweet proteins sweet? Interaction of
brazzein, monellin and thaumatin with the T1R2-T1R3
receptor. FEBS Lett 2002, 526:1-4.
13. Johnson C, Birch GG, MacDougall DB: The effect of the sweet-
ness inhibitor 2(-4-methoxyphenoxy)propanoic acid (sodium
salt) (Na-PMP) on the taste of bitter-sweet stimuli.  Chem
Senses 1994, 19:349-358.
14. Kawai M, Okiyama A, Ueda Y: Taste enhancements between
various amino acids and IMP. Chem Senses 2002, 27:739-745.
15. Lindley MG: Phenoxyalkanoic acid sweetness inhibitors. In
Sweeteners: Discovery, Molecular Design and Chemoreception Volume ASC
Symposiums Series 450. Edited by: Walters DE, Orthoefer FT and
DuBois GE. Washington, DC, American Chemical Society;
1991:251-260. 
16. Schiffman SS, Booth BJ, Sattely-Miller EA, Graham BG, Gibes KM:
Selective inhibition of sweetness by the sodium salt of +/-2-
(4-methoxyphenoxy)propanoic acid.  Chem Senses 1999,
24:439-447.
17. Sclafani A, Perez C: Cypha [propionic acid, 2-(4-methoxyphe-
nol) salt] inhibits sweet taste in humans, but not in rats. Phys-
iol Behav 1997, 61:25-29.
18. Jiang P, Cui M, Zhao B, Liu Z, Snyder LA, Benard LM, Osman R, Mar-
golskee RF, Max M: Lactisole interacts with the transmem-
brane domains of human T1R3 to inhibit sweet taste. J Biol
Chem 2005, 280:15238-15246.
19. Higuchi R, Krummel B, Saiki RK: A general method of in vitro
preparation and specific mutagenesis of DNA fragments:
study of protein and DNA interactions. Nucleic Acids Res 1988,
16:7351-7367.
20. Ueda T, Ugawa S, Yamamura H, Imaizumi Y, Shimada S: Functional
interaction between T2R taste receptors and G-protein
alpha subunits expressed in taste receptor cells. J Neurosci
2003, 23:7376-7380.